Search

FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label

FDA APPROVES CELLTRION, TEVA'S RITUXAN BIOSIMILAR, BUT WITH A NARROW LABEL

The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications...

PROCESS DEVELOPMENT FOR AN INDUCIBLE RITUXIMAB‐EXPRESSING CHO CELL LINE

Inducible mammalian expression systems are becoming increasingly available and are not only useful for the production of cytotoxic/cytostatic...

 
 
 
Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

BIO ROUNDUP: CMS BACKS CANCER TESTS, RIGHT TO TRY PASSES, ABBVIE SINKS

We'll start this week's roundup with several stories from Washington, D.C. that could have a lasting effect on public health. The FDA...

Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal

HALOZYME INKS $105M BRISTOL-MYERS PARTNERSHIP, EXPANDS ROCHE DEAL

Halozyme Therapeutics has turned a method of delivering a drug more conveniently into partnerships with several large pharmaceutical...